ANI PHARMACEUTICALS INC ANIP
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
7/9
Piotroski F — financial health
3.26
Altman Z″ — distress risk · safe
1.5%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $883.4M | $78.3M | — | $171.4M | $540.7M |
| 2024 | $614.4M | -$18.5M | — | $47.8M | $403.7M |
| 2023 | $486.8M | $18.8M | — | $110.1M | $432.7M |
| 2022 | $316.4M | -$47.9M | — | -$40.1M | $313.7M |
| 2021 | $216.1M | -$42.6M | — | $765,000 | $333.9M |
| 2020 | $208.5M | -$22.5M | — | $9.1M | $195.7M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 2026-06-12 | Sell | 500 | $82.03 |
| HAUGHEY THOMAS | director | 2026-06-08 | Sell | 2,000 | $80.88 |
| CAREY STEPHEN P. | SVP & CFO | 2026-06-05 | Option exercise | 3,312 | $49.51 |
| CAREY STEPHEN P. | SVP & CFO | 2026-06-05 | Sell | 3,312 | $80.00 |
| Leonard Matthew J | director | 2026-05-21 | Grant | 4,357 | — |
| HAUGHEY THOMAS | director | 2026-05-21 | Grant | 4,357 | — |
| Thoma Jeanne | director | 2026-05-21 | Grant | 4,357 | — |
| TANNENBAUM RENEE P | director | 2026-05-21 | Grant | 4,357 | — |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.26 (safe)
- Working capital / assets 0.33
- Retained earnings / assets -0.016
- EBIT / assets 0.077
- Equity / liabilities 0.601
Source: SEC EDGAR filings · CIK 0001023024 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.